Pulmonary Heart Disease and Remodeling

Moderators:

• Bradley A. Maron, MD, Associate Physician, Brigham and Women's Hospital
  Associate Professor of Medicine, Harvard Medical School
• Dr. Eileen Harder, MD, is a internal medicine specialist in Boston, MA. She currently practices at Brigham & Womens Hosp Emergency

How Does Pulmonary Disease Drive Pulmonary Vascular and Myocardial Remodeling? – Paul Hassoun, MD, Professor of Medicine, Johns Hopkins University; Director, Pulmonary Hypertension, Program Johns Hopkins Hospital

How Does Left Heart Disease Drive Pulmonary Vascular and Right Ventricular Remodeling? – Stephan Rosenkranz, MD, Professor, University of Cologne; Doctor, University of Cologne Heart Center

How Does Congenital Heart Disease Drive Pulmonary Vascular Remodeling? – Mary Mullen, MD, PhD, Assistant Professor in Pediatrics, Harvard Medical School; Associate in Cardiology, Boston Children’s Hospital

Right Heart Disease in the Absence of Pulmonary or Left Heart Disease – Michael Givertz, MD, Professor of Medicine, Harvard Medical School

Molecular Phenotyping of the Right Heart System: Is the Fog Starting to Clear? – Jane Leopold, MD, FACC, FAHA, FSCAI, Associate Professor of Medicine, Harvard Medical School; Director
Women’s Interventional Cardiology Health Initiative, Brigham and Women’s Hospital

Panel Discussion

Interventional Approaches to the Failing Right Heart

ECMO as a Bridge – Paul M. Heerdt, MD, PhD, Professor of Anesthesiology & Director of Applied Hemodynamics, Yale New Haven Hospital and Yale School of Medicine

Chromic Thromboembolic Pulmonary Hypertension: Surgical, Medical, and Interventional Options for Treatment – Piotr Sobieszczyk, MD, Instructor of Medicine, Harvard Medical School; Associate Physician, Brigham and Women’s Hospital

Percutaneous Approaches to RV Support Now and in the Future – Steven P. Keller, MD, Assistant Professor of Medicine and Biomedical Engineering, Johns Hopkins University

Panel Discussion

By the end of the session the participant will be able to:

• Discuss the importance of RV and pulmonary arterial coupling and its role in RV function and RV failure
• Evaluate the current data regarding myocardial metabolism and RV function
• Describe RV adaptation and maladaptation in pulmonary arterial hypertension (PAH) and the effectiveness and adequacy of current therapies used in management of PAH
• Given a patient case, formulate a management approach that takes into account RV structure, function, and maladaptation

ACCME Activity #202288293

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

• Moderator: Bradley A. Maron, MD: Steering Committee Member – Actelion; Investigator –Sponsored Research, Deerfield Corporation
• Paul Hassoun, MD: Paid Consultant – MS&D
• Paul M. Heerdt, MD, PhD: Paid consultant – Philips, BaudaxBio, Baxter
• Steven Keller, MD: Paid Consultant – Abiomed, Inc., X-COR Therapeutics, Inc., CBSET, Inc.; Advisor – Paragonix Technologies
• Jane A Leopold, MD: Research Funding – Aria CV, Astellas, Inc.; Consultant –Abbott Vascular; Speaker – United Therapeutics
• Stephan Rosenkranz, MD: Paid Consultant – Abbott, Acceleron, Actelion, Bayer, Janssen, MSD, Novartis, United Therapeutics, Vifor; Research Grants – Actelion, AstraZeneca, Bayer, Novartis, Janssen; Speaker – Actelion, Bayer, BMS, Ferrer, Janssen, MSD, Novartis, Pfizer, United Therapeutics, Vifor

Individuals with no conflicts of interest to disclose:

• Content reviewer: Charles J Turck, PharmD, BCPS, BCCCP, President, ScientiaCME
• Moderator: Eileen Harder, MD
• Michael Givertz, MD
• Mary P. Mullen, MD, PhD
• Piotr Sobieszczyk, MD

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

*Required to view Printable PDF Version